Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Weight Loss and SBBO in Parkinson's Disease
NCT01662791Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in Parkinson's disease (PD), sponsored by Mayo Clinic. Started Sep 2012; status: completed.
02
Drugs
rifaximin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01662791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662791.